Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ferry A L M Eskens

Showing results (1-10 of 76) with videos related to

Pageof 8
Sort By:
European Journal of Cancer (Oxford, England : 1990)|September 16, 2008
The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit?Ferry A L M Eskens, Stefan Sleijfer
European Journal of Cancer (Oxford, England : 1990)|November 14, 2006
The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a reviewFerry A L M Eskens, Jaap Verweij
Future Oncology (London, England)|December 21, 2012
Structure, development, preclinical and clinical efficacy of tivozanib (KRN-951, AV-951)Brigitte C M Haberkorn, Ferry A L M Eskens
Investigational New Drugs|August 2, 2003
Clinical trial design for target specific anticancer agentsRonald Hoekstra, Jaap Verweij, Ferry A L M Eskens
Biologics in Therapy|January 7, 2014
Current and Novel Treatment Options for Metastatic Colorectal Cancer: Emphasis on AfliberceptMaria H P Dietvorst, Ferry A L M Eskens
Journal of Surgical Oncology|September 28, 2018
FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort studyMustafa Suker, Joost J Nuyttens, Bas Groot Koerkamp, et al.
Investigational New Drugs|November 20, 2009
Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumorsNeeltje Steeghs, Hans Gelderblom, Judith Wessels, et al.
Thyroid : Official Journal of the American Thyroid Association|February 1, 2011
Sorafenib induced thyroiditis in two patients with hepatocellular carcinomaLeni van Doorn, Ferry A L M Eskens, Theo J Visser, et al.
Cancer Chemotherapy and Pharmacology|April 19, 2007
A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinomaRobert J Jones, Robert E Hawkins, Martin M Eatock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2004
A phase I and pharmacokinetic study of weekly paclitaxel and carboplatin in patients with metastatic esophageal cancerMarco B Polee, Alex Sparreboom, Ferry A L M Eskens, et al.
Pageof 8

Showing results (1-10 of 76) with videos related to

Sort By:
Pageof 8
European Journal of Cancer (Oxford, England : 1990)|September 16, 2008
The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit?Ferry A L M Eskens, Stefan Sleijfer
European Journal of Cancer (Oxford, England : 1990)|November 14, 2006
The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a reviewFerry A L M Eskens, Jaap Verweij
Future Oncology (London, England)|December 21, 2012
Structure, development, preclinical and clinical efficacy of tivozanib (KRN-951, AV-951)Brigitte C M Haberkorn, Ferry A L M Eskens
Investigational New Drugs|August 2, 2003
Clinical trial design for target specific anticancer agentsRonald Hoekstra, Jaap Verweij, Ferry A L M Eskens
Biologics in Therapy|January 7, 2014
Current and Novel Treatment Options for Metastatic Colorectal Cancer: Emphasis on AfliberceptMaria H P Dietvorst, Ferry A L M Eskens
Journal of Surgical Oncology|September 28, 2018
FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort studyMustafa Suker, Joost J Nuyttens, Bas Groot Koerkamp, et al.
Investigational New Drugs|November 20, 2009
Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumorsNeeltje Steeghs, Hans Gelderblom, Judith Wessels, et al.
Thyroid : Official Journal of the American Thyroid Association|February 1, 2011
Sorafenib induced thyroiditis in two patients with hepatocellular carcinomaLeni van Doorn, Ferry A L M Eskens, Theo J Visser, et al.
Cancer Chemotherapy and Pharmacology|April 19, 2007
A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinomaRobert J Jones, Robert E Hawkins, Martin M Eatock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2004
A phase I and pharmacokinetic study of weekly paclitaxel and carboplatin in patients with metastatic esophageal cancerMarco B Polee, Alex Sparreboom, Ferry A L M Eskens, et al.
Pageof 8